Cagrilintide
A long-acting amylin analog in development that promotes satiety through a different pathway than GLP-1 drugs.
Cagrilintide mimics amylin, a pancreatic hormone released alongside insulin at meals that tells the brain you're full, slows gastric emptying, and tempers glucagon. Engineering amylin to last a week was a chemistry feat — the natural hormone is notoriously unstable — and cagrilintide is the first long-acting analog to reach late-stage trials.
Alone it produces meaningful but moderate weight loss; combined with semaglutide as CagriSema, the two mechanisms stack. For patients, cagrilintide is worth knowing as the reason "amylin" keeps appearing in weight-medicine news: it represents the next pathway after GLP-1 and GIP, and a likely future option for people who respond poorly to current drugs.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Cagrilintide? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment